The Chairman, President & CEO of First Wave BioPharma, Inc. FWBI, James Sapirstein, recently graced Benzinga’s All-Access with his presence.
First Wave BioPharma stands as a clinical-stage biopharmaceutical company with a focus on developing targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company reports multiple promising therapies undergoing research across various indications related to GI diseases.
The full interview can be accessed here.
Featured photo by Hans Reniers on Unsplash.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
